Biotech companies saw the most notable insider purchases the past week, including the latest of the recent handful of biotech initial public offerings. It turns out that beneficial owners were behind most of those purchases.
A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a company because they believe the stock price will rise and they want to profit from it. Thus, insider buying can be an encouraging signal for potential investors.
Here are some of the more notable insider purchases that were reported in the past week.
This post originally appeared at 24/7 Wall St.